Clinical Data, Inc. Reports Results Of Phase I Studies Of Stedivaze™ Demonstrating Safety And Tolerability In Patients With Asthma And COPD
Links shared publicly online about this topic.
- 1,273total visits
Clinical Data, Inc. Reports Results Of Phase I Studies Of Stedivaze™ Demonstrating Safety And Tolerability In Patients With Asthma And COPD
View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2010 at 6:07 am By:
Clinical Data, Inc. Reports Results Of Phase I Studies Of Stedivaze™ Demonstrating Safety And Tolerability In Pa... http://mnt.to/3zHq
Also Shared By:
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea
news-medical.net — “Vicept Therapeutics, Inc. announced today positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.” View full resource at news-medical.net
Most Recently Shared on January 10, 2011 at 2:26 pm By:
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea: Vicept Therapeutics, Inc. an... http://bit.ly/fMvanz
Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients
news-medical.net — “Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.” View full resource at news-medical.net
Most Recently Shared on July 29, 2010 at 7:06 am By:
News-Medical.Net Health News and Oncology
Oncology News: Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients: A... http://bit.ly/au90Dz
Clinical Data, Inc. Reports Results of Phase I Studies of Stedivaze(TM) Demonstrating Safety and Tolerability in Patients with Asthma and COPD - MarketWatch
marketwatch.com — “Clinical Data, Inc. Reports Results of Phase I Studies of Stedivaze(TM) Demonstrating Safety and Tolerability in Patients with Asthma and COPD - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on March 30, 2010 at 2:08 pm By:
Michael Blaiss, MD Allergist, Physician, and Doctor
Results of Phase I Studies of Stedivaze(TM) Demonstrating Safety and Tolerability in Patients with Asthma and COPD http://is.gd/b6Hj4
Advertisement
medical_tweets
@medical_tweets
Clinical Data, Inc. Reports Results Of Phase I Studies Of Stedivazeâ„¢ Demonstrating Safety And Tolerability In Patie.. http://bit.ly/94YPgk
1 year ago...